IFNB1 and COVID-19: For example, in a double-blinded, placebo-controlled trial the combination of IFNβ plus remdesivir showed no clinical benefit when compared to remdesivir alone, suggesting no clinical benefits of the IFNβ therapy in patients with COVID-19 (143).